Evidence map›Paper›PMID 30343011›Full record

ArticlePapillomavirus research (Amsterdam, Netherlands)2018

Development and interlaboratory agreement of real-time PCR for HPV16 quantification in liquid-based cervical samples.

David Guenat, Véronique Dalstein, Frédéric Mauny, Maëlle Saunier, Jenny Briolat, Christine Clavel, Didier Riethmuller, Christiane Mougin, Jean-Luc Prétet

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Papillomavirus research (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

David GuenatEA3181, Université de Franche-Comté, COMUE Université Bourgogne Franche-Comté, LabExLipSTIC ANR-11-LABX-0021, Boulevard Alexandre Fleming, F-25030 Besançon Cedex, France; Centre National de Référence Papillomavirus, CIC 1431, CHU Besançon, F-25000, France.
Véronique DalsteinINSERM, UMR-S 1250, Reims, France; Champagne-Ardenne, Faculté de Médecine, Reims, France; CHU Reims, Laboratoire Biopathologie, Reims, France.
Frédéric MaunyUMR 6249 CNRS, F-25000 Besancon, France.
Maëlle SaunierEA3181, Université de Franche-Comté, COMUE Université Bourgogne Franche-Comté, LabExLipSTIC ANR-11-LABX-0021, Boulevard Alexandre Fleming, F-25030 Besançon Cedex, France.
Jenny BriolatINSERM, UMR-S 1250, Reims, France; Champagne-Ardenne, Faculté de Médecine, Reims, France; CHU Reims, Laboratoire Biopathologie, Reims, France.
Christine ClavelINSERM, UMR-S 1250, Reims, France; Champagne-Ardenne, Faculté de Médecine, Reims, France; CHU Reims, Laboratoire Biopathologie, Reims, France.
Didier RiethmullerEA3181, Université de Franche-Comté, COMUE Université Bourgogne Franche-Comté, LabExLipSTIC ANR-11-LABX-0021, Boulevard Alexandre Fleming, F-25030 Besançon Cedex, France.
Christiane MouginEA3181, Université de Franche-Comté, COMUE Université Bourgogne Franche-Comté, LabExLipSTIC ANR-11-LABX-0021, Boulevard Alexandre Fleming, F-25030 Besançon Cedex, France; Centre National de Référence Papillomavirus, CIC 1431, CHU Besançon, F-25000, France.
Jean-Luc PrétetEA3181, Université de Franche-Comté, COMUE Université Bourgogne Franche-Comté, LabExLipSTIC ANR-11-LABX-0021, Boulevard Alexandre Fleming, F-25030 Besançon Cedex, France; Centre National de Référence Papillomavirus, CIC 1431, CHU Besançon, F-25000, France. Electronic address: jean_luc.pretet@univ-fcomte.fr.
Inserm · FRCentre National de la Recherche Scientifique · FRUniversité Bourgogne Franche-Comté · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High risk HPV infection is the necessary cause for the development of precancerous and cancerous lesions of the cervix. Among HPV, HPV16 represents the most carcinogenic type. Since the determination of HPV16 DNA load could be clinically useful, we assessed quantitative real-time PCR targeting E6HPV16 and albumin genes on two different platforms. Series of SiHa cells diluted in PreservCyt were used to assess repeatability and reproducibility of two in-house real-time PCR techniques run in two different laboratories to determine HPV16 load. Furthermore, 97 HPV16 positive cervical samples were evaluated to estimate inter-center variability using Bland-Alman plots. As a whole, both techniques presented coefficients of variation for HPV16 load measurement similar to those established for other virus quantification with commercial kits. Moreover, the two real-time PCR techniques showed a very good agreement for HPV16 load calculation. Finally, we emphasize that robust HPV16 DNA quantification requires normalization of viral load by the cell number.

Indexed as

Cervix UteriFemaleHuman papillomavirus 16HumansOncogene Proteins, ViralPapillomavirus InfectionsReal-Time Polymerase Chain ReactionRepressor ProteinsReproducibility of ResultsViral LoadE6 protein, Human papillomavirus type 16Oncogene Proteins, ViralRepressor ProteinsAgreementCoefficient of variationPapillomavirusViral load

Identifiers

PMID30343011
PMCPMC6202657
OpenAlexW2896973689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.